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Summanr Bone metastases from prostate carcinoma are predominantly osteoblastic. Recentlv. unrnary
pyridinoline (Pyr) and deoxypyridinoline (Dpyr) have been employed as indicators of bone resorption. In this
studs. we evaluated urinary Py-r and Dpyr levels in 19 prostate carcinoma patients. of whom 12 had bone
metastasis and seven had not. and 11 age-matched control subjects. There was a significant difference in Pvr
levels between the control group and the patients with metastasis (mean ± s.d.. 19.5 ± 7.2 Vs
73.3 ± 67.1 nmol mmol-' creatinine. P<0.05). The mean level of Dpyr in the patients with metastasis
(10.8 ± 8.0 nmol mmolV' creatinine) was significantly higher than that in the control group
(3.1 ± .1 nmol mmol' creatinine. P <0.01). and also higher than that in the patients without metastasis
(3.5 ± 1.9nmolmmol-' creatinine. P<0.05). There was no significant difference in Py-r and Dpyr levels
between the control group and the patients without metastasis. These results suggest that bone resorption is
also accelerated in prostate carcinoma patients with bone metastasis.
Pvridinoline (Pyr). a cross-link within and between collagen
molecules. contributes to the stability of collagen fibres. and
is distributed mainly in bone. dentine and cartilage (Fujimoto
et al.. 1978). Deoxypyridinoline (Dpyr) is an analogue of Pyr
and reportedly has a greater specificity for bone and dentine
than does Pyr (Ogawa et al.. 1982: Evre. 1987). In the
process of bone resorption. Pyr and Dpyr are excreted in the
urine. and measurements of urinary. Pyr and Dpyr concentra-
tions have been used to estimate the degree of bone resorp-
tion (Robins et al.. 1991). Because Py-r and Dpyr have a high
specificity for bone. are not affected by diet and are not
internally metabolised. they mav be more useful markers of
bone resorption than other substances investigated so far
(Anon. 1992). We have previously investigated the signifi-
cance of urinarv Pyr and Dpyr as markers of bone resorption
in healthy subjects (Ohishi et al.. 1993) and in patients with
various bone metabolic diseases (Ohishi et al.. 1992.
1994).
It has been reported that urinary Pyr and Dpyr levels are
elevated in patients with osteoclastic bone metastases (Pater-
son et al.. 1991). and we have also obtained similar results.
On the other hand. the bone metastases associated with
prostate carcinoma are predominantly osteoblastic. In this
study. we investigated the usefulness of urinary Pyr and Dpyr
as markers of bone metastasis in patients with prostate car-
cinoma.
Materials and methods
The patients comprised 19 men (average age 77.9 years) with
prostate carcinoma examined at the Department of Urology
affiliated to Hamamatsu University School of Medicine
(Hamamatsu, Japan). All were referred for 99DTc-poly-
phosphate scintigraphy for evaluation of skeletal metastasis.
After evaluation of blood examination data and comparison
of areas showing increased skeletal activity with available
radiographs, we determined the patients to be positive or
negative for bone metastases. Among the patients, bone
metastases were observed in 12 (group with metastasis;
average age 80.0 years) and were absent in seven (group
without metastasis: average age 74.3 years). In addition. 11
healthy male volunteers (control group; average age 70.8
years) without bone metabolic disease were used as a control
group. Blood and urine were obtained between 09:00 h and
11:00 h and stored immediately at - 30'C until use.
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Urinar} Pyr and Dpyr levels were measured as described
previously (Takahashi et al.. 1993). Briefly. each urine sample
was hydrolvsed with an equal volume of concentrated hydro-
chloric acid at 110°C for 20 h. The hydrolysate (0.25 ml) was
mixed with 15 ml of distilled water and applied to an SP-
Sephadex C25 column (0.8 x 1.0 cm). After washing with
20 ml of 0.15 M hydrochloric acid. Pyr and Dpyr were eluted
with 5 ml of 1.0 M hydrochloric acid. After evaporation. the
residue was dissolved in 200 tl of 1% heptafluorobutyric acid
(HFBA) solution. The solutions were stored at - 30'C prior
to high-performance liquid chromatography (HPLC)
analysis.
The HPLC system consisted of a pump (model CCPM.
Tosoh. Tokyo. Japan). spectrofluorometer (model FS-8010.
Tosoh) and system controller (model SC-8010. Tosoh). A
column (8 mm x 10cm) prepacked with Radial-Pak C18. of
10pm particle size. type 8C1810u (Waters Associates. Mil-
ford. MA. USA) was used. A mobile phase of acetonitrile-
30 mM HFBA (27:73. v v) was employed at a flow rate of
1.0 ml min-'. The volume of each sample injected was 160 pl.
Fluorescence at 390 nm was measured upon excitation at
297 nm.
Before hydrolyis. the urinary creatinine content was deter-
mined enzymatically from an aliquot of each urine sample
using a Shimadzu CL-20 clinical chemistry analyser (Kyoto.
Japan). The values of urinary Pyr and Dpyr in urine samples
were expressed per mmol of urinary creatinine. Serum
alkaline phosphatase (AP) was measured by the modified
King-King method. and values were expressed in King Arm-
strong units (KAUs).
All values were expressed as means ± s.d. Differences
between groups were analysed by one-way analysis of
variance (ANOVA) followed by the Scheffe F-test using the
Stat View II program on an Apple Macintosh Computer.
P-values <0.05 were considered significant.
Results
The age. Pyr. Dpyr and AP levels and metastatic site of each
individual are listed in Table I. There was a significant
difference in Pyr level between the control group and the
patients with bone metastasis (mean ± s.d. 19.5 ± 7.2 *s
73.3 ± 67.1 nmol mmol-' creatimnne. P<0.05) (Figure 1).
Although the mean level of Pyr in the patients with bone
metastasis was higher than in the patients without bone
metastasis (73.3 vs 24.1 nmol mmol-' creatinine). the
difference was not statistically significant. The mean value of
Dpyr in the patients with metastasis was significantly higher
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Table I Levels of each marker in the patients
Age Pvr Dpyr AP Site of metastasis
1 74 11.6 1.8 6.2 None
2 69 16.6 0.8 2.9 None
3 69 16.8 2.7 4.8 None
4 74 22.2 3.3 5.0 None
5 71 26.4 6.3 6.0 None
6 84 28.6 5.2 0.2 None
7 79 46.4 4.4 8.9 None
8 78 28.0 3.0 15.2 Right femur
9 74 52.1 8.1 10.8 Pubis
10 77 125.6 25.3 12.8 Right femur
11 72 18.7 3.5 4.3 TI,2.6,7, L4, Sacrum
12 76 23.0 3.1 5.2 LI.3,4
13 78 26.8 5.6 3.8 L5, left femur, left radius
14 76 30.3 4.4 1.2 Multiple
15 89 44.4 6.7 7.9 T12, L1, left femur
16 88 49.6 15.5 30.4 Right humerus, ribs, L2
17 66 61.2 15.7 13.7 L1,2,3, left femur
18 95 190.1 23.0 156.0 Pubis, ilium, ischium
19 91 217.3 16.0 15.6 Left humerus, T3,8,9,12, L1,2
Data are expressed for each individual as: Pyr, Dpyr, nmol mmol
creatinine; AP. KAU. There was no significant difference among the
groups (patients without bone metastasis. 1-7; patients with one or
two bone metastases, 8-10; patients with three or more bone meta-
stases. 11-19) for each measurement parameters.
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Figure 2 Levels of deoxypyridinoline in the three groups. The
mean level for the group with bone metastasis was significantly
higher than that for the control group (P<0.05) and that for the
group without bone metastasis (P<0.01).
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Figre 1 Levels of pyridinoline in the three groups. The mean
level for the group with bone metastasis was significantly higher
(P<0.05) than that for the control group. The bold bar shows
the mean value and thin bar shows s.d.
than that in the control group (10.8 vs 3.1 nmol mmol-'
creatinine P<0.01), and also higher than that in the patients
without metastasis (3.5 nmol mmol-' creatinine, P<0.05)
(Figure 2). There was no significant difference in Pyr or Dpyr
levels between the control group and the patients without
bone metastasis. AP levels showed no significant differences
between any of these groups (Figure 3).
On considering all the measured values, there was a
significant correlation between Pyr and Dpyr (r = 0.833,
P<0.001), between Pyr and AP (r = 0.40, P<0.05) and
between Dpyr and AP (r=0.54, P<0.01).
D ion
Bone metastasis is a common event in the natural history of
prostate carcinoma. Moreover, autopsy and roentgenological
studies have revealed that bone metastases are of the pure
osteoblastic variety in over 50% of cases (Elkin & Mueller,
1954; Jacobs, 1983). It has been reported that, histologically,
there is little bone destruction as compared with new bone
Figwe 3 Levels of alkaline phosphatase in the three groups.
There were no significant inter-group differences. The lower bar is
less than 0.
formation, and that few osteoclasts but many active osteo-
blasts surrounded by stromal cell proliferation are present in
the bone metastases of patients with prostate carcinoma
(Aoki et al., 1986). Osteocalcin (bone gla protein, BGP) is
regarded as a marker of osteogenesis or bone formation.
According to Shih et al. (1990), serum osteocalcin levels are
high in prostate carcinoma patients with multiple bone
metastase, but not significantly different from those in
patients without bone metastasis.
However, bone resorption by osteoclasts is followed by
bone formation by osteoblasts in normal bone tissue. Bone
resorption and bone formation are thus coupled so that
continuous bone remodelling occurs. The significant correla-
tion observed between Pyr, Dpyr and AP in this study gave
added support to the coupling of bone resorption with bone
formation. Before urinary Pyr and Dpyr were adopted as
markers of bone turnover, urinary hydroxyproline, a measure
of bone resorption, was the only readily available index.
Urinary hydroxyproline was reported to be significantly in-
creased in prostate carcinoma patients with bone metastasis
(Kontturi et al., 1974; Bishop & Fellows. 1977). However.
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urinary hydroxyproline is affected by diet and reflects only
10% of the actual bone resorption rate. because it is
metabolised by the liver (Prockop, 1964).
In this study. we demonstrated that the levels of both Pyr
and Dpyr were increased significantly in the patients with
bone metastasis compared with the control group. Thus, our
results revealed that bone resorption was also accelerated in
the bone metastases of patients with prostate carcinoma.
despite the osteoblastic dominance associated with such
metastases on histological and radiographic grounds. More-
over a significant increase in urinary Dpyr was observed in
the patients with bone metastasis compared with the patients
without bone metastasis. This finding may indicate that Dpyr
is a more sensitive indicator of bone resorption than Pyr.
However, urinary Pyr and Dpyr measurements alone could
not differentiate bone resorption originating from bone
metastases from benign bone lesions (i.e. in the patient with
bone metastases who has osteoporosis, the values of urinary
Pyr and Dyr increase from the whole bone lesion. including
benign bone lesion). In conclusion. urinary Pyr and Dpyr are
useful diagnostic markers of bone metastasis although their
relation to other bone resorptive diseases also needs to be
examined.
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